INTRODUCTION
In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC). Here, report prespecified patien...
D. Yue, F. Cappuzzo, Wen-Xiang Wang et al.· Future Oncology· 0 citations
BACKGROUND
Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...
Chong-Rui Xu, Yan Zhang, G. Lin et al.· The Lancet· 1 citation
Respiratory diseases represent a severe global health burden. However, the clinical efficacy of conventional therapeutics is severely limited by complex pulmonary physiological barriers, including mucociliary clearance, alveolar-capillary barrier, and alveolar macrophage phagocytosis. Biomimetic nano drug delivery syst...
Shao-Huang Wu, Bingyi Lu, Hanjie Chen et al.· Journal of Controlled Releas...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.